| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/24/2003 | WO2003032920A2 Oligonucleotide modulation of cell adhesion |
| 04/24/2003 | WO2003032918A2 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors |
| 04/24/2003 | WO2003032913A2 Methods and compositions for targeting proteins across the blood brain barrier |
| 04/24/2003 | WO2003032907A2 High-concentration protein formulations and method of manufacture |
| 04/24/2003 | WO2003032906A2 Delivery of poorly soluble drugs |
| 04/24/2003 | WO2003032904A2 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| 04/24/2003 | WO2003032902A2 Tumor targeted photodiagnostic-phototherapeutic agents |
| 04/24/2003 | WO2003032901A2 Pathological tissue detection and treatment employing targeted benzoindole optical agents |
| 04/24/2003 | WO2003032900A2 Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications |
| 04/24/2003 | WO2003032899A2 Methods and materials for targeting and affecting selected cells |
| 04/24/2003 | WO2003032898A2 Modified human thymic stromal lymphopoietin |
| 04/24/2003 | WO2003032866A2 Detection and treatment of intravascular lesions |
| 04/24/2003 | WO2003032810A2 Treatment and diagnosis of insulin resistant states |
| 04/24/2003 | WO2003032809A2 Modulation of akt-dependent response to prevent restenosis |
| 04/24/2003 | WO2003032728A2 Methods for preventing or reversing asthma and compositions useful therefor |
| 04/24/2003 | WO2003032727A1 Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| 04/24/2003 | WO2003018608A8 Process for purifying glycopeptide phosphonate derivatives |
| 04/24/2003 | WO2003011887A3 Antisense modulation of apolipoprotein b expression |
| 04/24/2003 | WO2003005964A3 Recombinant vsv for the treatment of tumor cells |
| 04/24/2003 | WO2003004631A3 USE OF INHIBITORS OF EXPRESSION OR ACTIVITY OF p8/com1 FOR TREATING TUMORS. |
| 04/24/2003 | WO2003004612A3 Inhibitor of t cell activation |
| 04/24/2003 | WO2002102316A3 Histone deacetylase and methods of use thereof |
| 04/24/2003 | WO2002098907A3 Cation conducting gabaa receptors and their use |
| 04/24/2003 | WO2002098441A3 Method of treating metabolic disorders using neuronatin polypeptides |
| 04/24/2003 | WO2002095016A3 Champ - a cardiac helicase-like factor |
| 04/24/2003 | WO2002094201A3 Composition and method for treating cells |
| 04/24/2003 | WO2002090384A3 Antimicrobial polypeptide from aspergillus niger |
| 04/24/2003 | WO2002088180A3 Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds |
| 04/24/2003 | WO2002085295A3 Methods and compositions for the modulation of biofilm formation |
| 04/24/2003 | WO2002079420A3 Adam-like protease disruptions, compositions and methods related thereto |
| 04/24/2003 | WO2002079397A3 Virus derived antimicrobial peptides |
| 04/24/2003 | WO2002077187A3 Proteins producing an altered immunogenic response and methods of making and using the same |
| 04/24/2003 | WO2002074959A3 Human leucine-rich repeat containing protein expressed predominately in nervous system tissues, hlrrns1 |
| 04/24/2003 | WO2002072822A3 Als2 gene and amyotrophic lateral sclerosis type 2 |
| 04/24/2003 | WO2002070011A3 Treatment of ppar mediated diseases |
| 04/24/2003 | WO2002066626A3 Regulation of human mut/nudix nucleoside triphosphate pyrophosphohydrolase |
| 04/24/2003 | WO2002066490A3 Cationic sterol derivatives, ph-sensitive liposomes comprising cationic sterol derivatives and method for loading liposomes with active substances |
| 04/24/2003 | WO2002065129A3 Epitopic sequences for diagnosing infection by chlamydia trachomatis |
| 04/24/2003 | WO2002064154A3 Methods and compositions for inhibiting hiv-coreceptor interactions |
| 04/24/2003 | WO2002063000A9 Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same |
| 04/24/2003 | WO2002060436A8 Use of fredericamycin a and its derivatives in the treatment of pin1-associated states |
| 04/24/2003 | WO2002056900A3 Use of slpi for treating chronic inflammatory intestinal diseases |
| 04/24/2003 | WO2002055710A3 Regulation of human purple acid phosphatase |
| 04/24/2003 | WO2002055552A3 Soluble cyclic analogues of beta amyloid peptide |
| 04/24/2003 | WO2002053137A3 Pharmaceutical composition for treatment of phimosis using topical corticosteroid |
| 04/24/2003 | WO2002049576A9 Fab i and inhibition of apicomplexan parasites |
| 04/24/2003 | WO2002047710A3 Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer |
| 04/24/2003 | WO2002046383A3 Protein modification and maintenance molecules |
| 04/24/2003 | WO2002046231A3 Caml-binding peptides |
| 04/24/2003 | WO2002046227A3 Glp-1 fusion proteins |
| 04/24/2003 | WO2002045431A3 Genetically engineered herpes virus for the treatment of cardiovascular disease |
| 04/24/2003 | WO2002043741A3 Methylenetetrahydrofolate reductase inhibitors and use thereof |
| 04/24/2003 | WO2002038171A3 METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE |
| 04/24/2003 | WO2002036798A3 Inhibitors of transglutaminases |
| 04/24/2003 | WO2002031498A3 Protecting therapeutic compositions from host-mediated inactivation |
| 04/24/2003 | WO2002030980A3 Use of anti-human integrin alpha d antibodies to treat spinal cord injury |
| 04/24/2003 | WO2002030975A3 Antifungal peptides |
| 04/24/2003 | WO2002026825A3 G-protein coupled receptors |
| 04/24/2003 | WO2002024895A3 Transcription factors and zinc finger proteins |
| 04/24/2003 | WO2002022553A3 Non-natural basic amino acids, their preparation and use |
| 04/24/2003 | WO2002018585A8 Packaging of positive-strand rna virus replicon particles |
| 04/24/2003 | WO2002017952A3 Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
| 04/24/2003 | WO2002016615A3 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase |
| 04/24/2003 | WO2002016408A3 Gpe analogs |
| 04/24/2003 | WO2002014483A3 Human adenosine deaminase |
| 04/24/2003 | WO2002008273A3 47508, a novel human histone deacetylase family member and uses thereof |
| 04/24/2003 | WO2002006342A3 G-protein coupled receptors and nucleic acids encoding same |
| 04/24/2003 | WO2002004513A3 Down syndrome critical region 1-like 1 proteins |
| 04/24/2003 | WO2002000878A3 Human msp1 mitochondrial dynamin, its msp1-x isoforms, and their therapeutic use |
| 04/24/2003 | WO2001078796A3 Type ii gonadotropin-releasing hormone receptor and polynucleotides encoding therefor |
| 04/24/2003 | WO2001077389A3 Genes expressed in foam cell differentiation |
| 04/24/2003 | WO2001075440A3 Schizophrenia related genes |
| 04/24/2003 | WO2001062791A9 Control of tgf (beta) signaling by km23 superfamily members |
| 04/24/2003 | US20030079242 Animal model for use as tool in diagnosing and treating tumors |
| 04/24/2003 | US20030079239 Nucleotide sequences coding polypeptide for use in the treatment of osteoporosis |
| 04/24/2003 | US20030079237 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders |
| 04/24/2003 | US20030078532 Composite dressings for the treatment of wounds |
| 04/24/2003 | US20030078411 Adeno-associated virus capsid immunologic determinants |
| 04/24/2003 | US20030078409 Nucleotide sequences coding polypeptide for use in the treatment of respiratory system, asthmatic and inflammatory bowel diseases |
| 04/24/2003 | US20030078406 Methods and compositions for DRM, a secreted protein with cell growth inhibiting activity |
| 04/24/2003 | US20030078405 47 human secreted proteins |
| 04/24/2003 | US20030078396 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 04/24/2003 | US20030078391 Nucleotide sequences coding polypeptide for use in treatment of periodontal disease |
| 04/24/2003 | US20030078390 Tissue cement proteins from Rhipicephalus appendiculatus |
| 04/24/2003 | US20030078389 Gamma-heregulin |
| 04/24/2003 | US20030078388 Antibody mixture for use in human diagnostics and therapeutics |
| 04/24/2003 | US20030078386 Antibody for use in the treatment of viral, gastrointestinal, autoimmune and cell proiferative disorders |
| 04/24/2003 | US20030078378 Blocking expression of virulence factors in S. aureus |
| 04/24/2003 | US20030078377 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/24/2003 | US20030078376 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 04/24/2003 | US20030078375 Nucleotide sequences coding polypeptides for use in the tratment of ischemia-reperfusion injury, restenosis and parasitic diseases |
| 04/24/2003 | US20030078373 Chaperone fragments |
| 04/24/2003 | US20030078369 Apicidin-derived cyclic tetrapeptides |
| 04/24/2003 | US20030078368 Redox-stable, non-phosphorylated cyclic peptide inhibitors of SH2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use |
| 04/24/2003 | US20030078302 As carriers for delivering active agents such as peptides, drugs by administration, such as oral, subcutaneous, sublingual, and intranasal administration |
| 04/24/2003 | US20030078241 Treating effects of excessive reactive oxygen species |
| 04/24/2003 | US20030078226 Delivery of polypeptides by secretory gland expression |
| 04/24/2003 | US20030078221 Method for treating a Complement System-mediated disease comprising administering a pharmaceutically effective amount of a Nucleic Acid Ligand of a Complement System Protein; SELEX method |
| 04/24/2003 | US20030078220 Invention provides genetic variants of the human Interleukin 4 Receptor Alpha (IL4R alpha ) gene and methods for identifying which variants of this gene are possessed by an individual |
| 04/24/2003 | US20030078219 Compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 2; cancer therapy |